U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06976892) titled 'Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer' on April 03.
Brief Summary: Two drugs called Idetrexed and olaparib are being evaluated. Idetrexed is a type of drug called an "aFR-targeted thymidylate synthase inhibitor". Idetrexed has been designed to selectively target cancer cells that have a protein called folate receptor on the surface of cancer cells. Thymidylate synthase is key to cancer cells for creating new DNA when they multiply. Blocking the action of thymidylate synthase with a drug like Idetrexed may therefore stop cancers from growing by damaging DNA in cancer cells. Olaparib is a type of drug cal...